Tuesday, 17 November 2026 Every SEC filing alert, by company
ALFA USA Filings Every alert, straight from SEC EDGAR
News
Financial Results · Q3 2026

Tarsus Pharmaceuticals Q3 2026 Results: Net Loss of $668M, Loss Widens

Tarsus Pharmaceuticals reported a significant net loss of $693.9 million for the nine months ended September 30, 2026, primarily driven by $632.2 million in acquired in-process research and development expenses from the acquisitions of iRenix and Alkeus. Despite the net loss, total revenues grew to $530.5 million, up from $299.7 million in the prior year, fueled by strong product sales.

Q3 2026 at a glance · $ million
MetricQ3 2026Q3 2025
Revenue194.6118.7
Net income-668.3-12.6
EPS (diluted, $ a share)$-14.40$-0.30

A dash means the filing did not report that period. Growth is not shown when either period was a loss. Figures from the filing's XBRL data.

Growth and margins
Revenue, year on year+63.9%
Operating margin-340.3%
Source

10-Q filed with the SEC, NASDAQ: TARS. Figures from the filing's XBRL data; summary written with AI assistance from the filing.

Read the filing ↗

Tarsus Pharmaceuticals, Inc.: key numbers

Share price
$78.68Close, Nov 16
Market cap
$3.88B
Shares outstanding
49.31MLatest SEC cover page
Sector
Life Sciences
Industry
Biological Products, (No Diagnostic Substances)SIC 2836

Today's reference numbers, updated daily. Not a valuation or a recommendation.

More from Tarsus Pharmaceuticals, Inc.

All →
4:07 PM ET 8-K
Financial Results

Tarsus Pharmaceuticals Financial Results

Tarsus Pharmaceuticals reported record third quarter 2026 financial results, highlighted by XDEMVY net product sales of $194.6 million, a 64% year-over-year increase. The company surpassed one million bottles dispensed and $1 billion in cumulative net sales since the product's launch, while also announcing the appointment of Neera Clase as Chief Commercial Officer.

“XDEMVY has shown what that focus can achieve. In just three years since launch, we have dispensed more than one million bottles and generated $1 billion in cumulative net product sales, and with continued robust growth, we are only getting started. That strength is helping us build one of the most differentiated pipelines in eye care, with the potential to bring five medicines to patients in the next five years.”

Bobby Azamian, M.D., Ph.D., Chief Executive Officer and Chairman of Tarsus
4:01 PM ET 8-K/A
M&A Deal

Tarsus Pharmaceuticals M&A Deal with Alkeus Pharmaceuticals, Inc.

Tarsus Pharmaceuticals filed an amendment to its previous 8-K to provide required historical and pro forma financial statements following its acquisition of Alkeus Pharmaceuticals. The acquisition was originally completed on September 4, 2026, pursuant to a merger agreement dated July 31, 2026.

Counterparty
Alkeus Pharmaceuticals, Inc.

Get Alerts

Get ALFA Finder alerts first

Real-time SEC filing alerts for US stocks are launching soon. Leave your details and we'll tell you the moment they go live.